HUTCHMED (HCM) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

HUTCHMED HCM is currently developing the following drugs: Hmpl-A830, Hmpl-760, Rabeprazole And Hmpl-760, Hmpl-A580, Hmpl-760, R-Gemox, Hmpl-523, Hmpl-A251, Hmpl-523 Acetate Tablets, Hmpl-306, 100 Μci [14C] Hmpl-306, Hmpl-760 Planned Dose 1, R-Gemox, Hmpl-760 Planned Dose 2, Paclitaxel, Doxorubicin, Fruquintinib, Sintilimab, Hmpl-506, Hmpl-306 Regimen, Salvage Chemotherapy Regimen, Surufatinib Combined With Camrelizumab, Nab-Paclitaxel, And Gemcitabine, Nab-Paclitaxel Plus Gemcitabine, Surufatinib With Nab-Paclitaxel, And Gemcitabine, Tazemetostat, Hmpl-689, Fruquintinib+Sintilimab, Axitinib / Everolimus, Fruquintinib, Tazemetostat, Hmpl-A83 Injection, Hmpl-760, Surufatinib, Tislelizumab, Fruquintinib, Surufatinib And Tislelizumab _ Part 1, Surufatinib And Tislelizumab _ Part 2, Fruquintinib In Combination With Sintilimab, Hmpl-689. These drug candidates are in various stages of clinical development as the company works toward FDA approval.